Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis

Lionello Camba, Luca Aldrighetti, Fabio Ciceri, Massimo Bernardi, Sarah Marktel, Enzo Angeli, Maurizio Giacomelli

Research output: Contribution to journalArticle

Abstract

A 79-year-old patient with post-polycythaemic myelofibrosis presented with severe hypersplenism. After splenic artery catheterization, cytosine arabinoside was given intrasplenically from November 1999 to March 2000 for 5 d/month at 10 mg/m2 and increased each month by 10 mg/m2. It was then administered by continuous infusion until June 2000, starting at 20 mg/m2/d and tapering by 5 mg/m2 every 2 weeks to a final daily dose of 5 mg/m2/d. The drug was then stopped. The spleen had decreased to one third of the initial volume. Clinical conditions and haematological indices improved substantially. Intrasplenic therapy could be a new therapeutic tool for hypersplenism in chronic idiopathic and post-myeloproliferative myelofibrosis.

Original languageEnglish
Pages (from-to)638-640
Number of pages3
JournalBritish Journal of Haematology
Volume114
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Hypersplenism
Primary Myelofibrosis
Splenic Artery
Drug Therapy
Cytarabine
Catheterization
Spleen
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cytosine arabinoside
  • Hypersplenism
  • Locoregional chemotherapy
  • Myelofibrosis
  • Myeloproliferative disease

ASJC Scopus subject areas

  • Hematology

Cite this

Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis. / Camba, Lionello; Aldrighetti, Luca; Ciceri, Fabio; Bernardi, Massimo; Marktel, Sarah; Angeli, Enzo; Giacomelli, Maurizio.

In: British Journal of Haematology, Vol. 114, No. 3, 2001, p. 638-640.

Research output: Contribution to journalArticle

@article{8bacb8afd7114db4bf495a4b733315f9,
title = "Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis",
abstract = "A 79-year-old patient with post-polycythaemic myelofibrosis presented with severe hypersplenism. After splenic artery catheterization, cytosine arabinoside was given intrasplenically from November 1999 to March 2000 for 5 d/month at 10 mg/m2 and increased each month by 10 mg/m2. It was then administered by continuous infusion until June 2000, starting at 20 mg/m2/d and tapering by 5 mg/m2 every 2 weeks to a final daily dose of 5 mg/m2/d. The drug was then stopped. The spleen had decreased to one third of the initial volume. Clinical conditions and haematological indices improved substantially. Intrasplenic therapy could be a new therapeutic tool for hypersplenism in chronic idiopathic and post-myeloproliferative myelofibrosis.",
keywords = "Cytosine arabinoside, Hypersplenism, Locoregional chemotherapy, Myelofibrosis, Myeloproliferative disease",
author = "Lionello Camba and Luca Aldrighetti and Fabio Ciceri and Massimo Bernardi and Sarah Marktel and Enzo Angeli and Maurizio Giacomelli",
year = "2001",
doi = "10.1046/j.1365-2141.2001.02980.x",
language = "English",
volume = "114",
pages = "638--640",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis

AU - Camba, Lionello

AU - Aldrighetti, Luca

AU - Ciceri, Fabio

AU - Bernardi, Massimo

AU - Marktel, Sarah

AU - Angeli, Enzo

AU - Giacomelli, Maurizio

PY - 2001

Y1 - 2001

N2 - A 79-year-old patient with post-polycythaemic myelofibrosis presented with severe hypersplenism. After splenic artery catheterization, cytosine arabinoside was given intrasplenically from November 1999 to March 2000 for 5 d/month at 10 mg/m2 and increased each month by 10 mg/m2. It was then administered by continuous infusion until June 2000, starting at 20 mg/m2/d and tapering by 5 mg/m2 every 2 weeks to a final daily dose of 5 mg/m2/d. The drug was then stopped. The spleen had decreased to one third of the initial volume. Clinical conditions and haematological indices improved substantially. Intrasplenic therapy could be a new therapeutic tool for hypersplenism in chronic idiopathic and post-myeloproliferative myelofibrosis.

AB - A 79-year-old patient with post-polycythaemic myelofibrosis presented with severe hypersplenism. After splenic artery catheterization, cytosine arabinoside was given intrasplenically from November 1999 to March 2000 for 5 d/month at 10 mg/m2 and increased each month by 10 mg/m2. It was then administered by continuous infusion until June 2000, starting at 20 mg/m2/d and tapering by 5 mg/m2 every 2 weeks to a final daily dose of 5 mg/m2/d. The drug was then stopped. The spleen had decreased to one third of the initial volume. Clinical conditions and haematological indices improved substantially. Intrasplenic therapy could be a new therapeutic tool for hypersplenism in chronic idiopathic and post-myeloproliferative myelofibrosis.

KW - Cytosine arabinoside

KW - Hypersplenism

KW - Locoregional chemotherapy

KW - Myelofibrosis

KW - Myeloproliferative disease

UR - http://www.scopus.com/inward/record.url?scp=0034786174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034786174&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2001.02980.x

DO - 10.1046/j.1365-2141.2001.02980.x

M3 - Article

C2 - 11552991

AN - SCOPUS:0034786174

VL - 114

SP - 638

EP - 640

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -